Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Evaxion Biotech AS (EVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -78.3% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.28M USD | Price to earnings Ratio - | 1Y Target Price 10.85 |
Price to earnings Ratio - | 1Y Target Price 10.85 | ||
Volume (30-day avg) 101214 | Beta -0.23 | 52 Weeks Range 1.64 - 22.05 | Updated Date 03/30/2025 |
52 Weeks Range 1.64 - 22.05 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.8 |
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -57.38% |
Management Effectiveness
Return on Assets (TTM) -69.45% | Return on Equity (TTM) -802.8% |
Valuation
Trailing PE - | Forward PE 3.57 | Enterprise Value 14181658 | Price to Sales(TTM) 3.55 |
Enterprise Value 14181658 | Price to Sales(TTM) 3.55 | ||
Enterprise Value to Revenue 4.3 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 5578060 | Shares Floating 35887784 |
Shares Outstanding 5578060 | Shares Floating 35887784 | ||
Percent Insiders 25.25 | Percent Institutions 8.16 |
Analyst Ratings
Rating 4.5 | Target Price 10.85 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Evaxion Biotech AS
Company Overview
History and Background
Evaxion Biotech AS is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Founded in 2008, it has focused on leveraging its proprietary AI-immunology platform, PIONEER, to identify and develop novel therapies. Significant milestones include advancing its lead product candidates into clinical trials and securing partnerships to expand its research and development efforts.
Core Business Areas
- Oncology: Developing personalized cancer immunotherapies based on the patient's tumor mutations.
- Infectious Diseases: Creating prophylactic and therapeutic vaccines against various infectious diseases.
Leadership and Structure
The leadership team comprises experienced executives in biotechnology and pharmaceuticals. Organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- EVX-01: Personalized cancer immunotherapy targeting melanoma and non-small cell lung cancer (NSCLC). Market share data unavailable due to clinical stage. Competitors include BioNTech (BNTX) and Moderna (MRNA) in personalized cancer vaccines.
- EVX-B1: Prophylactic vaccine candidate targeting various bacterial infections. Market share data unavailable due to clinical stage. Competitors include Pfizer (PFE) and Merck (MRK) in vaccine development.
- EVX-M1: A cancer immunotherapy that targets specific mutations expressed on cancer cells to train the patients' own immune systems to attack cancer cells. Market share data unavailable due to clinical stage. Competitors include Gritstone Bio (GRTS).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. Personalized medicine and immunotherapy are growth areas.
Positioning
Evaxion Biotech AS is positioned as a pioneer in AI-driven immunotherapy development, focusing on personalized cancer treatments and infectious disease vaccines. Its competitive advantage lies in its PIONEER platform.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy and infectious disease vaccines is substantial, estimated to be in the tens of billions of dollars annually. Evaxion is positioned to capture a portion of this market through successful clinical development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary AI-immunology platform (PIONEER)
- Personalized immunotherapy approach
- Experienced leadership team
- Clinical-stage product candidates
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
- Early stage company with high execution risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the PIONEER platform to new therapeutic areas
- Successful clinical trial outcomes
- Advancements in AI and immunology
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- BNTX
- MRNA
- GRTS
- LLY
Competitive Landscape
Evaxion faces intense competition from larger pharmaceutical companies with greater resources and established commercial infrastructure. Its competitive advantage lies in its innovative AI-immunology platform and personalized approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as it is still early days for the company, with revenues dependant on partnership agreements.
Future Projections: Future growth is projected based on the success of its clinical programs and partnerships. Analyst estimates vary widely due to the inherent uncertainty in biotechnology development.
Recent Initiatives: Recent initiatives include advancing its EVX-01 and EVX-B1 programs in clinical trials and securing new partnerships and collaborations.
Summary
Evaxion Biotech AS is a clinical-stage company with a novel AI-driven platform for developing personalized immunotherapies. Its success hinges on positive clinical trial outcomes and strategic partnerships. The company faces significant competition and financial risks. If clinical trials are successful it may be subject to acquisition.
Similar Companies
- BNTX
- MRNA
- GRTS
- LLY
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evaxion Biotech AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://evaxion.ai |
Full time employees 49 | Website https://evaxion.ai | ||
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.